Immuneering Corp.'s lead program, IMM-1-104, for pancreatic ductal adenocarcinoma, receives Fast Track designation from the FDA.
Immuneering Corp. received Fast Track designation from the FDA for its lead clinical-stage program, IMM-1-104, to treat pancreatic ductal adenocarcinoma patients who have failed one line of treatment. The designation expedites the drug's development and review process. Immuneering plans to evaluate IMM-1-104 in pancreatic cancer and other tumor types in its Phase 1/2a study, with multiple readouts expected in 2024.
February 20, 2024
5 Articles